In view of this, AK2 has great potential for use in clinical diagnosis and prognosis of tumours based on monitoring of CDK4 biomarkers, while also holding promise as an intrabody-based anti-tumour therapy that acts by targeting intracellular CDK4. Here, CDK4 is linked to neoplasm.